World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
60
Citations
26774
World Ranking
3281
National Ranking
1527

Overview

Hyam I. Levitsky is affiliated with Johns Hopkins University in the United States. Their recent research contributions focus predominantly on immunology and immune cell function, with a particular interest in the reproductive system and pregnancy-related immunological processes.

Their recent papers include the following:

  • Abstract 6802: CXCR4 transgene improves in vivo migration and efficacy of engineered iPSC-derived natural killer cells, 2024, Cancer Research
  • Abstract 1320: Engineered expression of HLA-E and HLA-G protects iPSC-derived cells from killing by primary NK cells, 2024, Cancer Research
  • Abstract 3613: Screening iPSC lines for optimal characteristics of differentiation into immune effector cells for clinical programs, 2024, Cancer Research
  • POS0058 GENERATION OF iPSC-DERIVED CAR-NK, γδ CAR-T, AND αβ CAR-T CELLS WITH POTENT ACTIVITY FOR TREATMENT OF B CELL-MEDIATED AUTOIMMUNE DISEASES, 2025, Annals of the Rheumatic Diseases

Levitsky frequently collaborates with a team of researchers, including:

  • Daniel J. Perry
  • Liam Campion
  • Buddha Gurung
  • Michael Naso
  • Barry Morse

Their work is primarily published in the venue Cancer Research, with multiple publications there, as well as in Annals of the Rheumatic Diseases.

Levitsky's research spans the subfield of immunology, with their work emphasizing:

  • Immune cell function and interaction
  • Reproductive system and pregnancy

Best Publications

  • Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity

    Glenn Dranoff;Elizabeth Jaffee;Audrey Lazenby;Paul Golumbek

  • The Central Role of CD4+ T Cells in the Antitumor Immune Response

    Kenneth Hung;Robert Hayashi;Anne Lafond-Walker;Charles Lowenstein

  • Role of LAG-3 in regulatory T cells.

    Ching Tai Huang;Creg J. Workman;Dallas Flies;Xiaoyu Pan

  • Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

    Alex Y. C. Huang;Paul Golumbek;Mojgan Ahmadzadeh;Elizabeth Jaffee

  • Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

    Carola H. Ries;Michael A. Cannarile;Sabine Hoves;Jörg Benz

  • Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

    Eric R. Fearon;Drew M. Pardoll;Toshiuki Itaya;Paul Golumbek

  • Treatment of Established Tumors with a Novel Vaccine That Enhances Major Histocompatibility Class II Presentation of Tumor Antigen

    Ken Yu Lin;Frank G. Guarnieri;Kevin F. Staveley-O'Carroll;Hyam I. Levitsky

  • Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4

    Paul T. Golumbek;Audrey J. Lazenby;Hyam I. Levitsky;Liz M. Jaffee

  • Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

    Kevin Staveley-O’Carroll;Eduardo Sotomayor;Jami Montgomery;Ivan Borrello

  • Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer

    Jonathan W Simons;Bahar Mikhak;Ju-Fay Chang;Angelo M DeMarzo

  • Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by Ex Vivo Granulocyte-Macrophage Colony-Stimulating Factor Gene Transfer

    J.W. Simons;E.M. Jaffee;C.E. Weber;H.J. Levitsky

  • Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.

    Eduardo M. Sotomayor;Ivan M Borrello;Erev Tubb;Frédérique Marie Rattis

  • High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

    Leo Luznik;Javier Bolaños-Meade;Marianna Zahurak;Allen R. Chen

  • ENGINEERING AN INTRACELLULAR PATHWAY FOR MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II PRESENTATION OF ANTIGENS

    Tzyy-Choou Wu;F. G. Guarnieri;K. F. Staveley-O'carroll;R. P. Viscidi

  • Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

    Aurélien Marabelle;Holbrook Kohrt;Idit Sagiv-Barfi;Bahareh Ajami

  • Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.

    Gang Zhou;Charles G. Drake;Hyam I. Levitsky

  • Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.

    David J. Morgan;Huub T. C. Kreuwel;Shonna Fleck;Hyam I. Levitsky

  • Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression.

    Eduardo M. Sotomayor;Ivan Borrello;Frédérique Marie Rattis;Alex G. Cuenca

  • In Vivo Cross-Priming of MHC Class I–Restricted Antigens Requires the TAP Transporter

    Alex Y.C Huang;Allen T Bruce;Drew M Pardoll;Hyam I Levitsky

  • Cell polarity: an examination of its behavioral expression and its consequences for polymorphonuclear leukocyte chemotaxis.

    S H Zigmond;H I Levitsky;B J Kreel

Frequent Co-Authors

Elizabeth M. Jaffee
Elizabeth M. Jaffee Johns Hopkins University
Drew M. Pardoll
Drew M. Pardoll Johns Hopkins University School of Medicine
Richard J. Jones
Richard J. Jones Johns Hopkins University
Leo Luznik
Leo Luznik Johns Hopkins University
Ephraim J. Fuchs
Ephraim J. Fuchs Johns Hopkins University
B. Douglas Smith
B. Douglas Smith Johns Hopkins University
Allan D. Hess
Allan D. Hess Johns Hopkins University
Fray F. Marshall
Fray F. Marshall Emory University
Richard C. Mulligan
Richard C. Mulligan Harvard University
William G. Nelson
William G. Nelson Johns Hopkins University School of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students pursuing Immunology in the USA, exploring related online degrees can open doors to diverse healthcare careers. Many professionals in the field transition into advanced nursing roles, where specialized knowledge is critical. For instance, understanding fnp to acnp bridge program online options can help Family Nurse Practitioners move into Acute Care Nurse Practitioner roles, expanding their scope of practice.

Accelerated pathways are also popular, allowing students to fast-track their nursing careers. Programs like accelerated nurse practitioner program provide a faster route to becoming a nurse practitioner, which can be advantageous for those seeking to combine clinical expertise with immunological insights.

For those without a nursing background, enrolling in online rn programs for non nurses offers an accessible entry point into the profession. These programs prepare students for registered nursing roles, which are critical in immunology-related healthcare settings.

Career potential is another key consideration. Salary expectations vary by state and specialty; understanding how much does a dnp make can guide decisions about further education and specialization in the immunology field. Aligning educational paths with career goals ensures both professional growth and financial reward.

Best Scientists Citing Hyam I. Levitsky

Trending Scientists